Ginkgo Bioworks Holdings, Inc. (DNA)
NYSEHealth CareBiotechnologySnapshot 2026-11-04
$9.96-14.51%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · DNA
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-4.4) + peer(0.2*0.0) + term(0.0) → -1.53% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
today
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On November 5, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations w…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On August 5, 2026, Ginkgo Bioworks Holdings, Inc. announced its financial results for the second quarter ended June 30, 2026. A copy of the announcement is furnished with this Current Report on Form 8-K as Exhibit 99.1. Ginkgo announces material information to the public through a variety of means, including filings with the SEC, public conference calls, its website (https://www.ginkgo.bio), its investor relations website (https://investors.ginkg…
Results of Operations and Financial Condition. On May 7, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On February 26, 2026, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2025 and year ended December 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On November 6, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On August 7, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On May 6, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On February 25, 2025, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2024 and year ended December 31, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On November 12, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On August 8, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On May 9, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On February 29, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2023 and year ended December 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Results of Operations and Financial Condition. On November 8, 2023, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On August 9, 2023, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
Results of Operations and Financial Condition. On May 10, 2023, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.